Top

Journal of Cardiovascular Translational Research

Published in:

01-08-2019 | ß-Blockers | Original Article

Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure

Authors: Jasmine A. Luzum, Joseph D. English, Umair S. Ahmad, Jessie W. Sun, Benjamin D. Canan, Wolfgang Sadee, Joseph P. Kitzmiller, Philip F. Binkley

Published in: Journal of Cardiovascular Translational Research | Issue 4/2019

Abstract

Two common genetic polymorphisms in the beta-1 adrenergic receptor (ADRB1 Ser49Gly [rs1801252] and Arg389Gly [rs1801253]) significantly affect receptor function in vitro. The objective of this study was to determine whether ADRB1 Ser49Gly and Arg389Gly are associated with recovery of left ventricular ejection fraction (LVEF) in patients with heart failure. Patients with heart failure and baseline LVEF ≤ 40% were genotyped (n = 98), and retrospective chart review assessed the primary outcome of LVEF recovery to ≥ 40%. Un/adjusted logistic regression models revealed that Ser49Gly, but not Arg389Gly, was significantly associated with LVEF recovery in a dominant genetic model. The adjusted odds ratio for Ser49 was 8.2 (95% CI = 2.1–32.9; p = 0.003), and it was the strongest predictor of LVEF recovery among multiple clinical variables. In conclusion, patients with heart failure and reduced ejection fraction that are homozygous for ADRB1 Ser49 were significantly more likely to experience LVEF recovery than Gly49 carriers.

Available only for authorised users

Benjamin, E. J., Virani, S. S., Callaway, C. W., Chamberlain, A. M., Chang, A. R., Cheng, S., et al. (2018). Heart disease and stroke statistics—2018 update: a report from the American Heart Association (review-article). Circulation, 137(12), e67–e492. https://doi.org/10.1161/CIR.0000000000000558.CrossRefPubMed

Lupón, J., Díez-López, C., de Antonio, M., Domingo, M., Zamora, E., Moliner, P., et al. (2017). Recovered heart failure with reduced ejection fraction and outcomes: a prospective study. European Journal of Heart Failure, 19(12), 1615–1623. https://doi.org/10.1002/ejhf.824.CrossRefPubMed

Teeter, W. A., Thibodeau, J. T., Rao, K., Brickner, M. E., Toto, K. H., Nelson, L. L., et al. (2012). The natural history of new-onset heart failure with a severely depressed left ventricular ejection fraction: Implications for timing of implantable cardioverter-defibrillator implantation. American Heart Journal, 164(3), 358–364. https://doi.org/10.1016/j.ahj.2012.06.009.CrossRefPubMed

Merlo, M., Caiffa, T., Gobbo, M., Adamo, L., & Sinagra, G. (2018). Reverse remodeling in dilated cardiomyopathy: insights and future perspectives. International Journal of Cardiology: Heart & Vasculature, 18, 52–57. https://doi.org/10.1016/j.ijcha.2018.02.005.CrossRef

Mann, D., Kent, R., Parsons, B., & Cooper, G. (1992). Adrenergic effects on the biology of the adult mammalian cardiocyte. Circulation, 85(2), 790–804. https://doi.org/10.1161/01.CIR.85.2.790.CrossRefPubMed

MERIT-HF Study Group. (1999). Effect of metoprolol CR/XL in chronic heart failure: metoprolol CR/XL Randomised Intervention Trial in-Congestive Heart Failure (MERIT-HF). The Lancet, 353(9169), 2001–2007. https://doi.org/10.1016/S0140-6736(99)04440-2.CrossRef

Hernandez, A. F., Hammill, B. G., O'Connor, C. M., Schulman, K. A., Curtis, L. H., & Fonarow, G. C. (2009). Clinical effectiveness of beta-blockers in heart failure: findings from the OPTIMIZE-HF (Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure) registry. Journal of the American College of Cardiology, 53(2), 184. https://doi.org/10.1016/j.jacc.2008.09.031.CrossRefPubMedPubMedCentral

Podlowski, S., Wenzel, K., Luther, H. P., Müller, J., Bramlage, P., Baumann, G., et al. (2000). β1-Adrenoceptor gene variations: a role in idiopathic dilated cardiomyopathy? Journal of Molecular Medicine, 78(2), 87–93. https://doi.org/10.1007/s001090000080.CrossRefPubMed

Rathz, D. A., Brown, K. M., Kramer, L. A., & Liggett, S. B. (2002). Amino acid 49 polymorphisms of the human [beta] 1-adrenergic receptor affect agonist-promoted trafficking. Journal of Cardiovascular Pharmacology, 39(2), 155–160.CrossRefPubMed

10.

Liggett, S. B., Mialet-Perez, J., Thaneemit-Chen, S., Weber, S. A., Greene, S. M., Hodne, D., et al. (2006). A polymorphism within a conserved beta1-adrenergic receptor motif alters cardiac function and beta-blocker response in human heart failure. Proceedings of the National Academy of Sciences, 103(30), 11288–11293. https://doi.org/10.1073/pnas.0509937103.CrossRef

11.

Yancy, C. W., Jessup, M., Bozkurt, B., Butler, J., Casey, D. E., Drazner, M. H., et al. (2013). 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 62(16), e147–e239. https://doi.org/10.1016/j.jacc.2013.05.019.CrossRefPubMed

12.

Binkley, P. F., Lesinski, A., Ferguson, J. P., Hatton, P. S., Yamokoski, L., Hardikar, S., et al. (2008). Recovery of normal ventricular function in patients with dilated cardiomyopathy: predictors of an increasingly prevalent clinical event. American Heart Journal, 155(1), 69–74. https://doi.org/10.1016/j.ahj.2007.08.010.CrossRefPubMed

13.

Miller, S. A., Dykes, D. D., & Polesky, H. F. (1988). A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Research, 16(3), 1215–1215. https://doi.org/10.1093/nar/16.3.1215.CrossRefPubMedPubMedCentral

14.

1000 Genomes Project, C. (2015). A global reference for human genetic variation (article). Nature, 526, 68. https://doi.org/10.1038/nature15393.CrossRef

15.

Lanfear, D. E., Peterson, E. L., Zeld, N., Wells, K., Sabbah, H. N., & Williams, K. (2015). Beta blocker survival benefit in heart failure is associated with ADRB1 Ser49Gly genotype. Journal of Cardiac Failure, 21(8, Supplement), S50. https://doi.org/10.1016/j.cardfail.2015.06.169.CrossRef

16.

Talameh, J., Garrand, A., Ghali, J., Oren, R. M., Dunlap, S., Bakel, A. V., et al. (2012). Beta-1 adrenergic receptor genotype Ser49Gly is associated with beta-blocker survival benefit in patients with heart failure. Journal of the American College of Cardiology, 59(13, Supplement), E861. https://doi.org/10.1016/S0735-1097(12)60862-6.CrossRef

17.

Levin, M. C., Marullo, S., Muntaner, O., Andersson, B., & Magnusson, Y. (2002). The myocardium-protective Gly-49 variant of the β1-adrenergic receptor exhibits constitutive activity and increased desensitization and down-regulation. Journal of Biological Chemistry, 277(34), 30429–30435. https://doi.org/10.1074/jbc.M200681200.CrossRefPubMed

18.

Terra, S. G., Hamilton, K. K., Pauly, D. F., Lee, C. R., Patterson, J. H., Adams, K. F., et al. (2005). Beta1-adrenergic receptor polymorphisms and left ventricular remodeling changes in response to beta-blocker therapy. Pharmacogenetics and Genomics, 15(4), 227.CrossRefPubMed

19.

de Groote, P., Helbecque, N., Lamblin, N., Hermant, X., Mc Fadden, E., Foucher-Hossein, C., et al. (2005). Association between beta-1 and beta-2 adrenergic receptor gene polymorphisms and the response to beta-blockade in patients with stable congestive heart failure. Pharmacogenetics and Genomics, 15(3), 137–142. https://doi.org/10.1097/01213011-200503000-00001.CrossRefPubMed

20.

Nonen, S., Okamoto, H., Fujio, Y., Takemoto, Y., Yoshiyama, M., Hamaguchi, T., et al. (2008). Polymorphisms of norepinephrine transporter and adrenergic receptor α1D are associated with the response to β-blockers in dilated cardiomyopathy. The Pharmacogenomics Journal, 8(1), 78–84. https://doi.org/10.1038/sj.tpj.6500450.CrossRefPubMed

21.

Chen, L., Meyers, D., Javorsky, G., Burstow, D., Lolekha, P., Lucas, M., et al. (2007). Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol. Pharmacogenetics and Genomics, 17(11), 941. https://doi.org/10.1097/FPC.0b013e3282ef7354.CrossRefPubMed

22.

Perez, J. M., Rathz, D. A., Petrashevskaya, N. N., Hahn, H. S., Wagoner, L. E., Schwartz, A., et al. (2003). [Beta]1-adrenergic receptor polymorphisms confer differential function and predisposition to heart failure. Nature Medicine, 9(10), 1300. https://doi.org/10.1038/nm930.CrossRef

23.

Luo, M., Bi, Y., & Xu, Y. X. (2007). Effects of metoprolol on beta1 adrenergic receptor polymorphism and receptor density in urban Chinese patients with heart failure. Chinese Medical Journal, 120(19), 1720–1723.CrossRefPubMed

24.

Hu, H., Jui, H.-Y., Hu, F.-C., Chen, Y.-H., Lai, L.-P., & Lee, C.-M. (2007). Predictors of therapeutic response to beta-blockers in patients with heart failure in Taiwan. Journal of the Formosan Medical Association, 106(8), 641–648. https://doi.org/10.1016/S0929-6646(08)60021-2.CrossRefPubMed

25.

Metra, M., Covolo, L., Pezzali, N., Zacà, V., Bugatti, S., Carlo, L., et al. (2010). Role of beta-adrenergic receptor gene polymorphisms in the long-term effects of beta-blockade with carvedilol in patients with chronic heart failure. Cardiovascular Drugs and Therapy, 24(1), 49–60. https://doi.org/10.1007/s10557-010-6220-5.CrossRefPubMed

26.

Borjesson, M., Magnusson, Y., Hjalmarson, A., & Andersson, B. (2000). A novel polymorphism in the gene coding for the beta1-adrenergic receptor associated with survival in patients with heart failure. European Heart Journal, 21(22), 1853–1858. https://doi.org/10.1053/euhj.1999.1994.CrossRefPubMed

27.

Magnusson, Y., Levin, M. C., Eggertsen, R., Nyström, E., Mobini, R., Schaufelberger, M., et al. (2005). Ser49Gly of beta1-adrenergic receptor is associated with effective beta-blocker dose in dilated cardiomyopathy. Clinical Pharmacology and Therapeutics, 78(3), 221. https://doi.org/10.1016/j.clpt.2005.06.004.CrossRefPubMed

28.

Cresci, S., Kelly, R. J., Cappola, T. P., Diwan, A., Dries, D., Kardia, S. L., et al. (2009). Clinical and genetic modifiers of long-term survival in heart failure. Journal of the American College of Cardiology, 54(5), 432–444. https://doi.org/10.1016/j.jacc.2009.05.009.CrossRefPubMedPubMedCentral

29.

Sehnert, A. J., Daniels, S. E., Elashoff, M., Wingrove, J. A., Burrow, C. R., Horne, B., et al. (2008). Lack of association between adrenergic receptor genotypes and survival in heart failure patients treated with carvedilol or metoprolol. Journal of the American College of Cardiology, 52(8), 644–651. https://doi.org/10.1016/j.jacc.2008.05.022.CrossRefPubMed

30.

White, H. L., Boer, R. A., Maqbool, A., Greenwood, D., Veldhuisen, D. J., Cuthbert, R., et al. (2003). An evaluation of the beta-1 adrenergic receptor Arg389Gly polymorphism in individuals with heart failure: a MERIT-HF sub-study. European Journal of Heart Failure, 5(4), 463–468. https://doi.org/10.1016/S1388-9842(03)00044-8.CrossRefPubMed

31.

The Beta-Blocker Evaluation of Survival Trial Investigators. (2001). A trial of the beta-blocker bucindolol in patients with advanced chronic heart failure. New England Journal of Medicine, 344(22), 1659–1667. https://doi.org/10.1056/NEJM200105313442202.CrossRef

32.

Zou, C.-H., Zhang, J., Zhang, Y.-H., Wei, B.-Q., Wu, X.-F., Zhou, Q., et al. (2014). Frequency and predictors of normalization of left ventricular ejection fraction in recent-onset nonischemic cardiomyopathy. The American Journal of Cardiology, 113(10), 1705–1710. https://doi.org/10.1016/j.amjcard.2014.02.028.CrossRefPubMed

Title: Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure
Authors: Jasmine A. Luzum
Joseph D. English
Umair S. Ahmad
Jessie W. Sun
Benjamin D. Canan
Wolfgang Sadee
Joseph P. Kitzmiller
Philip F. Binkley
Publication date: 01-08-2019
Publisher: Springer US
Keywords: ß-Blockers
Heart Failure
Published in: Journal of Cardiovascular Translational Research / Issue 4/2019
Print ISSN: 1937-5387
Electronic ISSN: 1937-5395
DOI: https://doi.org/10.1007/s12265-019-09866-5

ACC 2024 Congress Coverage

Cardiology Video

Highlights from the ACC 2024 Congress

Watch now

Watch official videos from the ACC congress summarizing key highlights from the last year in heart failure, cardiomyopathies, valvular disease, pulmonary vascular disease, and pediatric cardiology.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Association of Genetic Polymorphisms in the Beta-1 Adrenergic Receptor with Recovery of Left Ventricular Ejection Fraction in Patients with Heart Failure

Abstract

ACC 2024 Congress Coverage

Highlights from the ACC 2024 Congress

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2019

MicroRNA-29b-3p Targets SPARC Gene to Protect Cardiocytes against Autophagy and Apoptosis in Hypoxic-Induced H9c2 Cells

Ex Vivo Pilot Study of Cardiac Magnetic Resonance Velocity Mapping for Quantification of Aortic Regurgitation in a Porcine Model in the Presence of a Transcatheter Heart Valve

A Novel Wireless Left Atrial Pressure Monitoring System for Patients with Heart Failure, First Ex-Vivo and Animal Experience

Profound Increase of Lung Airway Resistance in Heart Failure: a Potential Important Contributor for Dyspnea

A Durable Porcine Pericardial Surgical Bioprosthetic Heart Valve: a Proof of Concept

Loss of Regulatory Immune Function in Coronary Artery Disease Patients from the Indian Population

ACC 2024 Congress Coverage

Highlights from the ACC 2024 Congress

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page